Our papers very clearly acknowledge that the company, not the shareholders own the patents. But the shareholders own the company. As a matter of law, the shareholders are in privity with the company. As owners in privity with the company, the shareholders have an interest in the company's patents being recovered.
Almost a shame AMRN paid off the Pharmakon loan in Q4 - all of AMRN's patents were used as collateral for the loan, Pharmakon legally owned them, not AMRN - there would be no arguing that they didn't have legal standing to file this suit.
Market Data 
Markets 
AI
